Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GINYL
ADC Name
WO2018135501A1 ADC-9
Synonyms
WO2018135501A1 ADC9
   Click to Show/Hide
Organization
Daiichi Sankyo Co., Ltd.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Gastrointestinal stromal tumor [ICD11:2B5B]
Investigative
Drug-to-Antibody Ratio
7.4
Antibody Name
h046-Hwt/L6
  Antibody Info 
Antigen Name
G-protein coupled receptor 20 (GPR20)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2018135501A1_ADC-9 linker
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≍ 92.8
%
Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≍ 92.80% (Day 56) Positive GPR20 expression (GPR20+++/++)
Method Description
To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
References
Ref 1 Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate; 2018-07-26.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.